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Abstract
Context: Coronavirus Disease 2019 (COVID-19) pandemic has caused irreparable damage to society. The pediatric population may be
asymptomatic but has positive viral nucleic acid test results and plays an important role in spreading the infection in populations.
However, there is a substantial information gap on the epidemiology, pathology, and clinical presentations of COVID-19 in pediatric
patients.
Evidence Acquisition: English research articles published before April 18, 2020, were reviewed to understand the clinical charac-
teristics of SARS coronavirus 2, Severe Acute Respiratory Syndrome, and Middle East Respiratory Syndrome in children. The WHO
(https://www.who. int/) and CDC (Centers for Disease Control and Prevention, https://www.cdc.gov/) websites were also reviewed to
find eligible studies, besides articles extracted from PubMed, Scopus, and Google Scholar.
Results: In comparison with SARS and MERS, COVID-19 seems to have wider clinical symptoms and routes of transmission. Multi-
system inflammatory syndrome is a unique clinical feature of this novel virus. The low prevalence of COVID-19 in children may be
due to lower contacts or incomplete identification rather than resistance to the virus.
Conclusions: As this virus is novel, we believe that lessons learned from SARS and MERS outbreaks are very valuable in handling the
current pandemic. The aim of this paper was to provide the updated summary of clinical manifestation, diagnostic, molecular, and
genetic aspects of the novel coronavirus in comparison with SARS and MERS coronaviruses in children.
Keywords: SARS Coronavirus 2, Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, Children, Infection, Novel
Coronavirus
1. Context
In December 2019, an increasing number of unknown
viral pneumonia cases were reported from Wuhan, Hubei
Province, China. Soon after, more similar cases were re-
ported. By December 31, 2019, 27 cases of pneumonia with
an unknown etiology were reported to the World Health
Organization (WHO). The pathogen was identified as a
novel coronavirus in early January, and finally, on January
30, 2020, the WHO declared the novel coronavirus a pub-
lic health emergency of international concern (1-3). As of
April 18, 2020, more than 2,275,401 cases of 2019-nCoV infec-
tion were confirmed worldwide, with more than 150,000
deaths and 210 involved countries. Early cases showed a
positive history of a common zoonotic source of infection,
i.e., the Huanan Seafood Wholesale Market, while further
reports of infection in patients without any similar history
were suggestive of a new route for spreading infection (3,
4).
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Of more than 72,000 confirmed cases of 2019-nCoV up
to February 11 in the main land of China, 590 cases were un-
der the age of 19 years, which were mostly asymptomatic
or had mild clinical presentation. This explains the need
for accurate case detection in children (3). Although these
patients do not present typical clinical features of infec-
tion, they have positive viral nucleic acid test results and
can play an important role in spreading the infection in
populations (3). However, there is a substantial informa-
tional gap in the epidemiology, pathology, and clinical pre-
sentation of Coronavirus Disease 2019 (COVID-19) in pedi-
atric patients. It is still unknown whether the lower sever-
ity of the disease in the pediatric age group is due to the na-
ture of the virus, or it is because of better immunity during
childhood. Patients under 19-years-old comprise an impor-
tant group of asymptomatic carriers that need to be more
precisely and wisely studied. Here, we reviewed the cur-
rent situation of pediatric patients infected with COVID-
19 in comparison with Severe Acute Respiratory Syndrome
(SARS) and Middle East Respiratory Syndrome (MERS) pa-
tients.
2. Evidence Acquisition
In this review, research articles published before
April 18, 2020, were reviewed to understand the clini-
cal characteristics of COVID-19 in children. The WHO
(https://www.who. int/) and CDC (Centers for Disease Con-
trol and Prevention, https://www.cdc.gov/) websites were
also reviewed to find eligible studies, besides articles ex-
tracted from PubMed, Scopus, and Google Scholar. We
studied English articles with keywords, including chil-
dren, pediatric, COVID-19, SARS, MERS, and their equiva-
lents.
3. Results
3.1. Severe Acute Respiratory Syndrome
The novel coronavirus 2019 is a new member of the
family Coronaviridea and the genera beta coronavirus (1,
2). In November 2002, SARS cases were reported for the
first time from China, and soon after, the WHO enforced
a global effort to identify the causative agent of SARS. By
April, SARS coronavirus (SARS-CoV) was identified and char-
acterized as a new coronavirus. Although the passengers
who visited Fushin, China, were the main transporters of
the virus to other countries, more than 30% of the infected
patients were health care workers, suggesting a nosoco-
mial route of transmission as the main route of transmis-
sion for SARS coronavirus in adults. After more than 8,000
people were infected, and more than 700 deaths occurred
in 27 countries by July 2003, and no more cases were re-
ported, the WHO declared that the SARS outbreak was over
(5-9). Children were affected at a rate of 5% - 7% in the SARS
outbreak (10), and only 135 pediatric cases of SARS have
been well reported in the literature (11). Among probable
cases of SARS, more than 80% had a history of close contact
with confirmed cases of SARS, and only 10% had nosoco-
mial infections (11). According to such data from patients,
Bitnun et al. suggested that in the context of SARS-CoV
epidemics, every child with fever and positive history of
close contact with confirmed cases with or without respi-
ratory symptoms should be investigated for infection with
SARS-CoV (12). Secondary infection from confirmed cases
to other children and adults was less likely in young pa-
tients, while it was common among adult patients (13-15).
However, the report of three adults and one child infected
following close contact with an 11-year-old patient (5, 7) as-
sured the possibility of virus transmission from children
to other people (11). Female children were more involved,
and patients younger than 12 years of age only showed mild
symptoms and were less likely (2% according to available
data) to develop severe conditions (11).
Patients older than 12 years had similar clinical pre-
sentations to adults, and 11% of those who developed se-
vere conditions but survived were pediatric cases (≤ 18-
years-old) (11). Fever, cough, nausea, and vomiting were
the most common symptoms among pediatric cases (11).
Other symptoms included myalgia, chills, and headache,
which were more common among children older than 12
years (11). Diarrhea, although was common among adults,
occurred only in 23% of pediatric patients (11, 16). Radio-
graphic findings, including patchy infiltrates, opacities,
and areas of consolidation with multifocal lesions, pre-
dominantly in lower lobes, were detected in infected pedi-
atrics from the early onset of symptoms, which was in con-
trast to reports from adult patients (11, 17). The most com-
mon laboratory test findings among pediatric patients in-
cluded lymphopenia, leukopenia, thrombocytopenia, and
elevated levels of lactate dehydrogenase (LDH) and alanine
aminotransferase (ALT) (17-19). However, lymphopenia was
not detected in a group of children who did not receive cor-
ticosteroids (12, 20). In children, the most sensitive test for
the confirmation of infection was Reverse Transcriptase-
Polymerase Chain Reaction (RT-PCR) for the RNA of SARS-
CoV in nasal aspirate or Broncho alveolar lavage specimens
(11, 21). It was notable that the appropriate timing of sam-
pling was most important in the positivity of the test. The
best time for sampling was when there was a high viral
load in the patient, although the viral load in children had
never reached the level of adult patients (12, 20). The RNA
of the virus was detected in 48% of young patients within
five to seven days of the symptom onset (12, 21). Since
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there was still a lack of case definition with high sensitiv-
ity and specificity for patient detection, laboratory tests
were of most accuracy for the diagnosis of SARS in pedi-
atrics (11). Thus, SARS seems to present with mild symp-
toms in young patients, and only may patients with severe
disease develop further complications, including exercise
intolerance and residual lesions in CT scan (12, 20). The
SARS infection should be differentiated from other respi-
ratory viral infections, including influenza virus A, parain-
fluenza virus 3, respiratory syncytial virus, varicella zoster
virus, and rota virus, and also streptococcus pneumonia
(12). Patients without SARS-CoV infection rarely show ab-
normalities in chest radiography; however, all children
suspected for SARS-CoV infection should be investigated
for co-infections, especially with influenza viruses (12, 22).
3.2. Middle East Respiratory Syndrome
In June 2012, a man with evidence of viral pneumo-
nia developed multi-organ failure and died in Saudi Ara-
bia. Soon after, the causative agent was detected and re-
ported as a new coronavirus, Middle East Respiratory Syn-
drome coronavirus (MERS-CoV). Middle East Respiratory
Syndrome had been one of the challenging viral infec-
tions of the respiratory tract among hospitalized patients
all over the world. By January 2018, 2,143 cases were con-
firmed for MERS-CoV infection, with more than 700 deaths
(23-28). According to the WHO report, 36 cases were un-
der 19-years-old, which suggested that pediatrics were af-
fected with a rate of 2% in the MERS outbreak (10, 29-31).
MERS-CoV involved female children more than male chil-
dren (29). Similar to SARS, most of the cases had a positive
history of household contact (29, 32). Healthcare workers
are at a higher risk of infection with coronaviruses, which
is mostly due to the production of bio-aerosols (33, 34).
Since most pediatric cases only developed mild symptoms
and were rarely in need of hospital visits or admissions, the
rates of contact and infection transmission to healthcare
workers from children and vice versa were much lower
than that occurred by adults (35). However, sporadic MERS-
CoV infection was seen in patients with no past medical
or contact history (36). Almost all of the infected chil-
dren were asymptomatic or had mild symptoms. Available
data suggest that 56% (9/15) of infected cases had no spe-
cific symptoms in primary stages and only 37% (6/15) de-
veloped mild symptoms, while 18% (3/15) of the patients
with background diseases (cardiac disease, nephrotic syn-
drome, and cystic fibrosis) developed severe conditions,
two-thirds of whom died (29, 32, 36-40). Fever and mild
respiratory symptoms were common among symptomatic
cases, while severe respiratory distress only happened in
patients with comorbidities (29). It was notable that only
pediatric cases with MERS who had associated comorbidi-
ties developed renal failure and had poor outcomes (29,
32). Radiologic findings of MERS-CoV in children showed
bilateral diffuse infiltrates (36). Other infectious agents
such as influenza virus A, rhinoviruses, and enteroviruses
were common among patients with a clinical diagnosis
of MERS, which should be ruled out in suspected cases of
MERS (41). Due to the mild clinical picture of MERS and
SARS in children, there is only limited literature available
for pediatricians, while the early diagnosis of infected pe-
diatrics is of high importance in controlling the transmis-
sion of infection.
3.3. Coronavirus Disease 2019
The pediatric population is infected with COVID-19 to a
similar extent to the adult population when contact with
a case of COVID-19 occurs (42). However, initial epidemio-
logical studies showed that less than 3% of confirmed cases
were under 19-years-old (3). As of February 19, 2020, among
391 confirmed cases of COVID-19 in Shenzhen, China, 84%
had a positive history of at least one close contact with a
confirmed case (42, 43). Similar to SARS and MERS, close
contact plays the most important role in the transmis-
sion of the new coronavirus among pediatric patients (44).
Some cases were asymptomatic at the time of diagnosis
and were tested for the viral RNA during screening for
close contacts with previously confirmed cases (4, 22, 45,
46). The detection of case clusters in an early stage af-
ter a patient is confirmed for 2019-nCoV infection helps in
narrowing the spread of the virus. Of 1,184 case clusters
detected in China, 64% were reported for familial house-
holds. In Singapore, the study of 18 hospitalized patients
with PCR-confirmed 2019-nCoV infection, two family clus-
ters showed exposure to four infected cases, affirming the
important role of family clusters in the spread of COVID-
19 (3, 47). Similar to SARS and MERS outbreaks, female pe-
diatrics are more involved in the COVID-19 pandemic (4,
22, 45, 46). The youngest patient confirmed for infection
with COVID-19 was a neonate aged less than one-week-old,
which is younger than the youngest SARS and MERS pa-
tients, who aged nine and seven months, respectively (10,
45), suggesting the wide spectrum of ages that can be in-
fected with the novel coronavirus. The majority of pedi-
atric cases are asymptomatic or have mild symptoms (3)
and rarely progress into ARDS stage and multi-organ fail-
ure (22, 46, 48). The incubation period is 2 - 10 days among
the symptomatic patients (22). The most common symp-
toms among reported cases are fever and cough, although
sore throat, stuffy nose, sneezing, and rhinorrhea have also
been reported in some cases (22, 46). The most common
clinical presentations and imaging results among pedi-
atric cases of COVID-19 are listed in Table 1. While a rate
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of 20% - 30% deaths is reported for patients older than
60 years, only one death in pediatric patients has been re-
ported in China (3, 49). Nasopharyngeal swabs for nucleic
acids of COVID-19 virus using PCR become negative within
6-22 days of symptom onset in all patients (22, 46). The
virus also has been detected in other secretions of patients.
The RNA of the virus is detectable in the fecal samples of
patients even within 18-30 days after the onset of symp-
toms while they may have no gastrointestinal symptoms
(22, 50). Evidence of viremia was reported for only one case
in Singapore (50), but the RNA of the virus has still not
been detected in the urine (22). Co-infection with influenza
virus and rhinoviruses was evaluated among some cases,
but no patient has been detected with co-infection with in-
fluenza virus (22).
3.4. Transmission of COVID-19
The children-to-adult transmission of COVID-19 is pos-
sible (22); however, it has been a key question since the
early days of the pandemic, and more epidemiological
studies are needed to identify the role of children in the
transmission of COVID-19 to other children or adults (51).
One hypothesis for the lower severity of COVID-19 in the pe-
diatric group is the non-efficient transmission of the virus,
which may result from its specific molecular signaling and
receptor molecules in children. A well-known example
for the efficacy of transmission is the influenza virus. The
H1N1 virus binds to its specific receptors in the upper res-
piratory tract and causes mild symptoms in patients while
the H7N9 virus binds to its specific receptors in the lower
respiratory tract and causes more severe symptoms than
does H1N1 (52). In the case of coronaviruses, SARS-CoV and
NL63-CoV can cause different severities of disease in pa-
tients, while they bind to the same receptor, Angiotensin
Converting Enzyme 2 (ACE 2) (52). However, more data
on the molecular pathogenesis of COVID-19 in children are
needed to confirm whether the severity of the disease is de-
pendent on the molecular pathogenesis of the virus or not.
3.5. Angiotensin Converting Enzyme 2 Dilemma
The COVID-19 virus has recently been known to bind to
Angiotensin Converting Enzyme 2 (ACE2), which was pre-
viously known as the specific receptor for SARS-CoV (2, 28,
53-55). The binding of SARS-CoV to ACE2 is responsible for
lung injury during SARS (56). It is well known that when
SARS-CoV spike glycoproteins bind to this receptor, ACE2
is downregulated and results in the over production of
Angiotensin 2 (AG2) (28). Over-stimulation of type 1a An-
giotensin 2 receptors by AG2 increases pulmonary vessels
permeability and further lung damage (57). It is suggested
that the rapid progression of severe respiratory symptoms
of SARS-CoV in patients is associated with higher expres-
sion of its receptor, ACE2 (58, 59). The expression of ACE2
studied in several adult tissues showed different expres-
sions in different tissues (58). A small proportion of alve-
olar type 2 (AT2) cells of the human lungs has been re-
cently known to highly express ACE2 (60). Other cells of
human lungs that express ACE2 with lower ratios are AT1
cells, airway epithelial cells, fibroblasts, endothelial cells,
and macrophages (60). The expression of ACE2 is more in
adult males than in females, as seen in the epidemiologi-
cal data of COVID-19, possibly leading to the higher involve-
ment of adult males than the female population (3, 60).
The age-dependent variation in host responses in ARDS was
studied by Schouten et al. and it showed to be related to
the ACE2 level in patients (61). However, there were signif-
icant variations in ACE2 activity among pediatric patients,
which made it difficult to detect even small differences in
the levels of ACE2 between pediatrics and adults (61). An-
other study showed that the expression of ACE2 increases
in young male children as they grow up, while it decreases
in females as puberty changes begin (62). According to
the similarities between SARS-CoV and 2019-nCoV molecu-
lar pathways of pathogenesis, the demonstration of ACE2
expression and activity in the pediatric age group might
show the molecular basis for the lower severity of COVID-
19 in the pediatric group.
3.6. Multisystem Inflammatory Syndrome
Despite the lower severity of COVID-19 in the pedi-
atric population, since May 2020 during the COVID-19 pan-
demic, pediatricians have faced critically ill cases present-
ing with fever, rash, and multi-organ failure similar to pa-
tients with Kawasaki disease or toxic shock syndrome (63,
64). The condition in children is called Multi-System In-
flammatory Syndrome in Children (MIS-C). The association
between COVID-19 and MIS-C is not fully understood, and
it is not clear who is most at risk for this illness. One hy-
pothesis on the pathogenesis of MIS-C is the relationship
between the viral load and host response. In cases with low
viral loads, interferon (IFN) response results in viral clear-
ance and mild disease. In genetically susceptible hosts or
high viral loads, IFN responses may delay due to virus repli-
cation. Subsequently, the cytokine storm may be seen be-
fore viral clearance (65).
3.7. Detection of COVID-19 in Children
The confirmation of suspected cases of COVID-19 is
based on the Polymerase Chain Reaction (PCR) test to de-
tect the RNA of the virus in samples taken from nasopha-
ryngeal swabs or bronchoalveolar lavage (BAL). A positive
test result means that the RNA of the 2019-nCoV virus is
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Table 1. Clinical Presentation and Imaging Findings of Pediatric Patients with SARS, MERS, and COVID-19
SARS MERS COVID-19
Age range 50 days-17.9 years 9 months-17 years 1 day-18 years
Gender
Male 46% 62% 56.60%
Female 54% 38% 43.40%
Case definition Laboratory confirmeda Laboratory confirmeda Laboratory confirmeda
Fever > 38 Yes Yes Yesb
Cough Yes Yes Yes
Myalgia Yes Yes Less common
Malaise Yes Yes Less common
Rhinorrhea 22% Less common 8% - 13%
Dyspnea/tachypnoea/shortness of breath Yes Yes Yes
Pharyngeal congestion/sore throat Yes, sore throat Less common Yes, pharyngeal congestion
Vomiting/nausea Yes Yes Yes
Diarrhea/constipation Yes Less common Yes
Headache Yes Less common Yes
Mild/asymptomatic NA 47% More than 50%
Radiographic signs of pneumonia at onset of
illness
48% 100% Bilateral diffused infiltrate 22% Unilateral pneumonia, 56% Bilateral
pneumonia (patchy shadows or lung
consolidations) in chest CT
Radiographic changes during the course of
illness
97% NA 75% Multiple patch-like shadows, 75% GGO, 12%
White lung appearance, 12% Pleural effusion, 12%
Multiple mottling
Leukopenia 47% NA Less than 15%
Lymphopenia 46% NA Common
Increased CRP NA Yes Yes
Increased LDH 63% NA Less common
ICU admission 10% 18% Less than 5%
Case fatality rate 9.60% 35.50% 3-3.5%
Case fatality rate with comorbidities (%) 46% 60% 73%
Supplementary oxygen therapy 27% 25% Less common
Abbreviations: GGO, ground glass opacity; NA, not available
aConfirmed infection by PCR and/or ELISA in the main land of China.
bWe refused to use exact figures due to the lack of wide spectrum retrospective studies on the clinical presentations of children infected with COVID-19 in the literature
and the daily increasing number of patients worldwide.
present in the nasopharyngeal mucosal membrane. The
RNA of the virus was detected in blood samples of some
severe cases of adult patients (66), which was assumed to
be due to the severity of the disease (22). Viremia is re-
ported in the pediatric group of patients, too. One in-
fant was reported with a positive blood test for 2019-nCoV
with no symptoms during hospital admission except an
episode of 38.5ºC fever during the course of viremia, which
got relieved after one hour with no medications (50). The
RNA of the virus has also been detected in fecal samples
of some confirmed cases of COVID-19 in the young age
group (22). There is no report of diarrhea or other gas-
trointestinal symptoms in pediatric patients infected with
2019-nCoV (22), while diarrhea was common in SARS pa-
tients. Previous studies also reported high expression of
ACE2 in smooth muscle cells and endothelium of vessels
of the stomach, small intestine, and colon, as well as ente-
rocytes of the small intestine (58). According to these re-
ports, the GI tract seems to be a new site of replication for
2019-nCoV and emerges to establish more caution on the
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transmission of the virus through GI secretions of young
age patients. Many epidemiologic studies should be done
to examine the different aspects of COVID-19 and factors af-
fecting COVID-19, especially in children.
4. Conclusions
In conclusion, the natural course of coronaviruses in
children is still not defined and needs more precise stud-
ies seeking the nature and behavior of the virus among
pediatric patients with the hope of discovering a cure for
COVID-19. The low prevalence of COVID-19 in children may
be due to the incomplete identification rather than resis-
tance to the virus. SARS-CoV-2 has a wide range of transmis-
sion, clinical, and laboratory presentations in comparison
with SARS and MERS, which has made it difficult to erad-
icate. As the pandemic is still ongoing around the globe,
more pediatric cases may be reported in the near future
with similar or different clinical manifestations and we
need a high degree of suspicion for COVID-19 infection in
the pediatric population.
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